

# Silvia Reina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9383334/publications.pdf>

Version: 2024-02-01

27  
papers

295  
citations

758635

12  
h-index

940134

16  
g-index

27  
all docs

27  
docs citations

27  
times ranked

361  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Solanesyl-diphosphate Synthase Localizes in Glycosomes of Trypanosoma cruzi. Journal of Biological Chemistry, 2006, 281, 39339-39348.	1.6	35
2	Autoantibodies against cerebral muscarinic cholinceptors in Sjögren syndrome: functional and pathological implications. Journal of Neuroimmunology, 2004, 150, 107-115.	1.1	29
3	Anti-M3 muscarinic cholinergic autoantibodies from patients with primary Sjögren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E2 (PGE2) from the submandibular glands. Archives of Oral Biology, 2011, 56, 413-420.	0.8	21
4	Role of anti- $\alpha_1$ adrenergic antibodies from patients with periodontitis in cardiac dysfunction. Journal of Oral Pathology and Medicine, 2012, 41, 242-248.	1.4	21
5	Elevated IL-1 $\beta$ levels in anti-Ro/SSA connective tissue diseases patients with prolonged corrected QTc interval. Clinical and Experimental Rheumatology, 2015, 33, 715-20.	0.4	19
6	Human mAChR antibodies from Sjögren syndrome sera increase cerebral nitric oxide synthase activity and nitric oxide synthase mRNA level. Clinical Immunology, 2004, 113, 193-202.	1.4	16
7	Cholinergic Autoantibodies in Sjögren Syndrome. Journal of Dental Research, 2007, 86, 832-836.	2.5	16
8	Anti-brain cholinergic auto antibodies from primary Sjögren syndrome sera modify simultaneously cerebral nitric oxide and prostaglandin biosynthesis. International Immunopharmacology, 2007, 7, 1535-1543.	1.7	16
9	Cholinergic autoantibodies from primary Sjögren's syndrome modulate submandibular gland Na <sup>+</sup> /K <sup>+</sup> -ATPase activity via prostaglandin E <sub>2</sub> and cyclic AMP. European Journal of Oral Sciences, 2010, 118, 131-138.	0.7	16
10	Nitric Oxide Synthase and PGE2 Reciprocal Interactions in Rat Dental Pulp: Cholinergic Modulation. Journal of Endodontics, 2007, 33, 142-147.	1.4	13
11	Pro-apoptotic effect of anti- $\alpha_1$ -adrenergic receptor antibodies in periodontitis patients. International Immunopharmacology, 2012, 14, 710-721.	1.7	13
12	Signal transduction underlying carbachol-induced PGE2 generation and cox-1 mRNA expression of rat brain. Neuropharmacology, 2005, 48, 757-765.	2.0	12
13	Muscarinic cholinergic activation by pilocarpine triggers apoptosis in human skin fibroblast cells. Journal of Cellular Physiology, 2010, 222, 640-647.	2.0	10
14	Anti-M3 peptide IgG from Sjögren's syndrome triggers apoptosis in A253 cells. Cellular Immunology, 2012, 275, 33-41.	1.4	9
15	Endogenous signalling system involved in parotid gland adenosine A1 receptor-amylase release. Acta Physiologica, 2006, 186, 29-36.	1.8	7
16	Differential signalling pathways involved in cholinergic-dependent stimulation of nitric oxide isoforms in dental pulp. International Endodontic Journal, 2007, 40, 544-552.	2.3	6
17	Signaling pathways leading to prostaglandin E2 production by rat cerebral frontal cortex. Prostaglandins Leukotrienes and Essential Fatty Acids, 2006, 74, 255-262.	1.0	5
18	Action of anti-M <sub>3</sub> muscarinic acetylcholine receptor $\alpha$ -G of primary Sjögren's syndrome on the enzymatic antioxidant system in rat submandibular gland. Journal of Oral Pathology and Medicine, 2015, 44, 876-883.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Autoantibodies to the $\beta_1$ -Adrenoceptor from Patients with Periodontitis as a Risk Factor for Cardiac Dysfunction. <i>ISRN Dentistry</i> , 2011, 2011, 1-9.	1.5	5
20	Influence of lidocaine on ouabain-induced inotropic response in rat atria. <i>Biochemical Pharmacology</i> , 2003, 66, 1871-1877.	2.0	4
21	$\beta_1$ -Adrenoceptor antibody-induced increase in soluble CD40 ligand release in chronic periodontitis patients: role of prostaglandin $E_2$ . <i>Experimental Physiology</i> , 2012, 97, 1030-1039.	0.9	4
22	Immune Mediators against <i>Toxoplasma Gondii</i> during Reactivation of Toxoplasmic Retinochoroiditis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 949-957.	1.0	4
23	Atorvastatin inhibits the inflammatory response caused by anti-M3 peptide IgG in patients with primary Sjögren's syndrome. <i>Inflammopharmacology</i> , 2012, 20, 267-275.	1.9	3
24	Modulation of c-Jun NH <sub>2</sub> -Terminal (JNK) by Cholinergic Autoantibodies from Patients with Sjögren's Syndrome. <i>Pharmacology &amp; Pharmacy</i> , 2011, 02, 256-265.	0.2	2
25	Salivary inflammatory mediators and metalloproteinase 3 in patients with chronic severe periodontitis before and after periodontal phase I therapy. <i>Oral Biology and Dentistry</i> , 2013, 1, 3.	0.7	2
26	Interferon- $\beta$ and IL-10 Release Assay for Patients with Ocular Toxoplasmosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2239-2243.	0.6	1
27	Cholinergic Autoantibodies from Primary Sjögren's Syndrome Inhibit Mucin Production via Phospholipase C and Cyclooxygenase-2 In the Rat Submandibular Gland. <i>Dental Research Journal</i> , 2011, 8, 138-45.	0.2	1